teleo-codex/inbox/queue/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period.md

type	title	author	url	date	domain	secondary_domains	format	status	priority	tags	processed_by	processed_date	enrichments_applied	extraction_model
source	FDA TEMPO Pilot Manufacturer Selection Still Pending; CMS ACCESS Model Applications Due April 1, 2026 (First Performance Period July 1, 2026)	FDA / CMS (synthesized from multiple regulatory sources)	https://www.fda.gov/medical-devices/digital-health-center-excellence/tempo-digital-health-devices-pilot-frequently-asked-questions	2026-04-01	health		thread	enrichment	medium	TEMPO FDA CMS ACCESS-model digital-health hypertension CKM reimbursement regulatory	vida	2026-04-01	tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md	anthropic/claude-sonnet-4.5

Content

Status as of April 1, 2026 — synthesized from legal firm analyses and FDA FAQ:

TEMPO selection status:

• FDA began receiving statements of interest January 2, 2026
• FDA began sending follow-up requests to potential participants around March 2, 2026
• As of April 1, 2026: No formal public announcement of selected manufacturers has been made
• FDA has NOT published a formal program start date or selection decision timeline beyond "following review of submitted materials and follow-up responses"

CMS ACCESS model timeline — CRITICAL:

• ACCESS model applications were DUE April 1, 2026 (today)
• First performance period begins July 1, 2026
• TEMPO participants will need FDA follow-up + approval to coordinate with ACCESS enrollment
• This creates a practical crunch: TEMPO selection needs to happen in April/May 2026 for manufacturers to operationalize before July 1

Scope: Up to 10 manufacturers per clinical area:

1. Early CKM: hypertension, dyslipidemia, obesity/overweight with central obesity marker, prediabetes
2. CKM: diabetes, chronic kidney disease, atherosclerotic CVD
3. Musculoskeletal: chronic musculoskeletal pain
4. Behavioral health: depression or anxiety

Who this benefits: Traditional Medicare patients enrolled in the ACCESS model — excludes Medicaid, uninsured, commercial insurance. This population skews 65+.

The structural contradiction (from Session 16):

• TEMPO advances digital health for Medicare (65+, typically less severe hypertension prevalence)
• OBBBA dismantles Medicaid and SNAP coverage for working-age poor (highest hypertension non-control rate)
• These two policy trajectories diverge further as TEMPO moves to implementation

Agent Notes

Why this matters: The TEMPO selection still being pending 2 months after statements of interest closed suggests either (1) high volume of applications requiring extended review, or (2) the FDA is being careful about the first cohort since TEMPO is precedent-setting. The July 1, 2026 ACCESS model start creates urgency — manufacturers need TEMPO approval before then to participate in the first performance period.

What surprised me: ACCESS model applications were due TODAY (April 1, 2026). This means healthcare systems applying to ACCESS are doing so without yet knowing which TEMPO-approved devices they can use. This creates a chicken-and-egg problem: health systems need to know what tools they can deploy, but TEMPO selection isn't finalized.

What I expected but didn't find: Any announced TEMPO participants or early manufacturer news. The digital health investment community has been anticipating this announcement — if any companies have been selected, it would be significant news in health tech.

KB connections:

• Session 16: TEMPO pilot archives (FDA + CMS creating digital health infrastructure for Medicare + hypertension) — this is the status update
• Session 16: TEMPO + OBBBA structural contradiction — the divergence continues: TEMPO advancing while OBBBA SNAP cuts escalate
• CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system — TEMPO + ACCESS is a more sophisticated version of this dynamic

Extraction hints:

• Not yet extractable as a claim (insufficient evidence outcome)
• Follow up in next session: has TEMPO selection been announced?
• If July performance period launches as planned: which companies are the first TEMPO participants? This shapes the market landscape for digital health HTN management.

Curator Notes (structured handoff for extractor)

PRIMARY CONNECTION: Session 16 TEMPO archives + CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system

WHY ARCHIVED: Status update on TEMPO — selection still pending as of April 1, 2026. ACCESS applications due today. Sets up next session's follow-up.

EXTRACTION HINT: Not extractable as a standalone claim yet. Wait for TEMPO selection announcement. The structural contradiction (TEMPO + OBBBA divergence) is extractable once TEMPO participants are known — it needs specific examples to be credible.

Key Facts

• TEMPO accepts up to 10 manufacturers per clinical area across four categories: (1) Early CKM (hypertension, dyslipidemia, obesity/overweight, prediabetes), (2) CKM (diabetes, chronic kidney disease, atherosclerotic CVD), (3) Musculoskeletal (chronic pain), (4) Behavioral health (depression/anxiety)
• ACCESS model applications were due April 1, 2026
• ACCESS model first performance period begins July 1, 2026
• TEMPO manufacturer selection was still pending as of April 1, 2026, two months after statements of interest opened
• ACCESS model serves Traditional Medicare patients only, excluding Medicaid, uninsured, and commercial insurance populations